Search

everythinglearnresearchcommunity

for

Search:↓

A user has been using finasteride for 3 years with good results but wants to switch to dutasteride due to a plateau. They are seeking an online pharmacy that delivers dutasteride to Europe.

The user is discussing their hair loss treatment stack, which includes CB-03-01, Fluridil, Alfatradiol, Cosmerna, microneedling, and Stemoxydine. They have seen some new hair growth but wish they could use finasteride.

The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.

Finasteride and dutasteride are discussed as preventative treatments for hair loss, with some advocating for early use and others concerned about side effects, especially before full maturity. Many regret not starting these treatments earlier due to their effectiveness in preventing or slowing hair loss.

The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.

A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.

The conversation is about the perceived risks of oral minoxidil compared to spironolactone for treating hair loss, with the original poster currently taking spironolactone due to concerns about oral minoxidil's safety.

Woman uses antiandrogens for hair thinning prevention, experiences severe dry eye with finasteride. Asks if dutasteride could be better despite potential for worse dry eye.

Concerns about the effectiveness of DHT inhibitors like finasteride and minoxidil due to potential polymorph issues. Experts suggest these concerns are largely unfounded, especially compared to rare cases like ritonavir.

Topical spironolactone 5% is being discussed for its effectiveness in treating hair loss, specifically receding temples. The user is inquiring if it works similarly to finasteride as a testosterone blocker.

Blood work is recommended before starting finasteride. Minoxidil and RU58841 are also discussed as treatment options for hair loss.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Dutasteride is more effective than finasteride for hair loss, with some users experiencing fewer side effects. Users share experiences with dutasteride, finasteride, minoxidil, and biotin, discussing dosage and fertility concerns.

The conversation discusses the potential offering of oral finasteride/dutasteride and oral minoxidil treatments for hair loss, with feedback on pricing and preferences for separate or combined pills. Users express concerns about high costs, preferring affordable options, and some prefer oral over sublingual minoxidil for ease of use.

Finasteride may take over two years to show results and can cause side effects like sexual dysfunction and emotional changes. Alternatives such as dutasteride and minoxidil are discussed, with varying effectiveness and side effects.

The conversation is about whether dissolving finasteride in water affects its effectiveness. The user is concerned about the impact of water on the medication's efficacy over five days.

Hair loss discussion mentions treatments like Finasteride, Dutasteride, and Minoxidil. Users share experiences, side effects, and advice on using these treatments.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A user reports persistent sexual side effects three months after stopping finasteride, despite a healthy lifestyle and supplements. They express concern over the lack of libido and infrequent erections.

A 22-year-old male experienced significant hair regrowth and stopped shedding after using dutasteride and spironolactone for 3-4 months. Spironolactone is discussed as an antiandrogen, typically used for women or transitioning individuals, and not commonly recommended for men due to potential side effects.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

The conversation discusses hair loss treatments, including finasteride, minoxidil, estradiol, and spironolactone, with a focus on their effects on hair regrowth and gender transition. The original poster shares their personal experience with these treatments, emphasizing that estradiol and spironolactone should not be used by those who want to maintain a masculine appearance.

Switching from spironolactone to bicalutamide caused severe hair shedding, despite using treatments like dutasteride, minoxidil, and estradiol injections. The user is experiencing androgenetic alopecia and is seeking solutions to stop the hair loss.

Finasteride is effective for treating male pattern baldness (MPB) with minimal side effects, and topical finasteride is similarly effective. Dutasteride is also effective but less understood, and Minoxidil is less effective than Finasteride.

Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.